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Objective: Nephropathic cystinosis is an autosomal recessive lysosomal storage disorder that
is  characterised by the accumulation of the amino acid cystine in several body tissues due
to  a mutation in the CTNS gene, which encodes the cystinosin protein. The aim of this study
was  to sequence the coding exons of the CTNS gene in ﬁve different Jordanian families and
one  family from Sudan with nephropathic cystinosis.
Methods: Probands initially presented with Fanconi syndrome symptoms. An eye exami-
nation  showed the accumulation of cystine crystals in the cornea by the age of 2 years,
suggesting cystinosis. All of the coding exons and ﬂanking intronic sequences and the
promoter  region of the CTNS gene were ampliﬁed using polymerase chain reaction and
subjected to sequencing.
Results: None of the probands in this study carried the European 57-kb deletion in the CTNS
gene.  Seven variants in the coding and promoter sequence of the CTNS gene were identiﬁed
in  the probands of this study. Two of these variants were a CTNS mutation that was previously
identiﬁed in a heterozygous genotype in two different patients of European descendant. The
two  mutations were c.829dupA in exon 10 and c.890G>A in exon 11. The proband of family
2  was compound-heterozygous for the two mutations.
Conclusion: This study is the ﬁrst molecular study of infantile nephropathic cystinosis in
Jordan.  We  successfully identiﬁed the causative CTNS mutations in Jordanian families. The
results  provide a basis for the early detection of the disease using molecular tools in a highly
consanguineous Jordanian population.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open  access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Análisis  molecular  del  gen  CTNS  en  familias  jordanas  afectadas  por
cistinosis  nefropática
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Objetivo: La cistinosis nefropática es una enfermedad de almacenamiento lisosómico
autosómica recesiva que se caracteriza por la acumulación del aminoácido cistina en varios
tejidos  del cuerpo. Ello se debe a una mutación en el gen CTNS, que codiﬁca la proteína
cistinosina. El objetivo de este estudio fue secuenciar los exones codiﬁcantes del gen CTNS
en  cinco familias jordanas afectadas por la cistinosis.
Métodos: Los casos índice se presentaron inicialmente con síntomas del síndrome de Fan-
coni.  Exámenes oftalmológicos revelaron la acumulación de cristales de cistina en la córnea
a  la edad de 2 an˜os, lo que sugería la existencia de cistinosis. Todos los exones codiﬁcantes,
las  secuencias intrónicas ﬂanqueantes y la región promotora del gen CTNS se ampliﬁcaron
mediante  reacción en cadena de la polimerasa y fueron objeto de secuenciación.
Resultados: Ninguno de los casos índice de este estudio presentaba la deleción 57-kb europea
en  el gen CTNS. Se identiﬁcaron siete variantes en las secuencias codiﬁcante y promo-
tora  del gen CTNS en los casos índice de este estudio. Dos de estas variantes eran una
mutación  del gen CTNS previamente identiﬁcada en un genotipo heterocigótico de dos
pacientes  de descendencia europea. Las dos mutaciones eran c.829dupA en el exón 10 y
c.890G>A  en el exón 11. El caso índice de la familia número 2 era heterocigótico compuesto
respecto  a las dos mutaciones.
Conclusión: El presente estudio es el primer estudio molecular sobre cistinosis nefropática
infantil  en Jordania. Logramos identiﬁcar con éxito las mutaciones en el gen CTNS cau-
sante  en familias jordanas. Los resultados sirven de base para la detección precoz de esta
enfermedad mediante herramientas moleculares en una población jordana marcadamente
consanguínea.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo  Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Cystinosis is an autosomal recessive disease with a
1/100,000- to 1/200,000-live-birth prevalence.1 A combination
of physical mapping and linkage analysis successfully linked
cystinosis to a region on chromosome 17p13, and the CTNS
gene was positionally cloned and sequenced, with several
mutations identiﬁed in families with cystinosis.2,3 The CTNS
gene consists of 12 exons, of which exons 1 and 2 and the ﬁrst
19 nucleotides of exon 3 constitute the non-coding region of
the gene.3
According to the Human Gene Mutation Database
(http://www.hgmd.cf.ac.uk/ac/index.php – assessed 2014 Jul
11), more  than 100 mutations have been characterised thus
far in the CTNS gene. Recent studies from the Middle East
have identiﬁed several CTNS mutations, some of which were
new.4–10 The c.681G>A CTNS mutation is the most prevalent
mutation in Middle Eastern countries, whereas the founder
57-kb deletion mutation is the most common mutation
that is detected in northern European populations.3,4,7,10,11
Both the precise telomeric and centromeric breakpoints
for the 57-kb deletion were mapped by sequencing more
than 200 kb harbouring the CTNS gene using overlapping
BAC clones that were constructed from chromosome 17.12
Several molecular assays were developed to screen for the
57-kb deletion mutation, including multiplex PCR analy-
sis using primer pairs within and outside of the deletion
breakpoints and FISH analysis.13,14 Worldwide, the mutation
spectrum of the CTNS mutation is heterogeneous, as several
mutation types have been described in Italian, French, Ger-
man  and Swiss origin, Mexican, Indian and Thai and Spanish
populations.15–22
Clinically, cystinosis is classiﬁed into three different types
depending on the disease severity and the age of manifes-
tation. These forms include infantile (OMIM: 219800) and
juvenile (OMIM: 219900) nephropathic cystinosis and the ocu-
lar non-nephropathic (OMIM: 219750) form. The infantile form
is the most common type of the three clinical variants of cysti-
nosis and presents in the ﬁrst year of life with the renal tubular
electrolyte imbalance termed “Fanconi syndrome”; the patient
reaches end-stage renal disease by the age of 10 years if not
treated with cysteamine.23
The CTNS gene encodes a seven-transmembrane-domain
(TM) lysosomal protein called cystinosin, whose localisation to
the lysosome is guided by two sorting signals; a tyrosine-based
sorting signal that is located at the c-terminus of the protein
and a novel sorting signal that is located between the ﬁfth and
sixth transmembrane domains of the protein.24 The deletion
of either one of the two sorting signals results in partial mislo-
calisation of the cystinosin protein to the plasma membrane,
and a lysosomal signal is also observed.24 A whole COS-7 cell
functional assay demonstrated that cystinosin is a proton-
driven cystine transporter from the lysosome; these ﬁndings
form a foundation for understanding the molecular patho-
genesis of cystinosis, on which several genotype-phenotype
studies have been published.18,25,26
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The promoter of the CTNS gene was functionally charac-
terised using several chloramphenicol acetyltransferase (CAT)
gene reporter constructs.27 The basal CTNS promoter was
deﬁned as the region between nucleotide −316 to +1.27 Three
regulatory cis-elements were functionally characterised in the
CTNS promoter, two  of which harboured the Sp-1 transcription
factor binding site.27 A promoter mutation (−295G>C) in the
distal Sp-1 binding site was previously identiﬁed in one cysti-
nosis patient.27 In another functional study, CTNS promoter
constructs harbouring the −294 T mutant allele of the Sp-1
binding site also showed reduced activity.28 Here, we report for
the ﬁrst time the molecular basis for cystinosis in Jordanian
patients.
Methods
Probands  and  families
This study was approved by the joint institutional review board
committee of the Jordan University of Science and Technology
and King Abdullah University Hospital. Consent was obtained
from the patients’ parents and from the parents themselves
for family 6. All of the patients were Jordanians except for the
proband of family 5 who  was Sudanese.
In family 1, the proband was a 4-year-old female born to
ﬁrst-cousin parents. At the age of 2 years, she began to have
recurrent urinary tract infections. She was diagnosed with
hypothyroidism and also found by ultrasound to have nephro-
calcinosis. At the age of 4 years, she showed signs of Genu
Varum and bowed legs and was found to have rickets. She
was then referred to us, where she was diagnosed with Fan-
coni syndrome. Slit lamp examination conﬁrmed the presence
of crystals in the cornea, suggesting cystinosis. DNA samples
from her sister, grandmother (father’s side), and parents were
available for testing.
In family 2, the proband was 5 years and 3 months old
and born by normal vaginal delivery to second-cousins par-
ents with a birth weight of 2.18 kg. She was found to have
failure to thrive, hypokalaemia, hyponatraemia, hypochlo-
raemia, polyuria and polydipsia, suggesting Fanconi syn-
drome. An X-ray at 18 months showed signs of rickets, and a
slit-lamp examination of the cornea conﬁrmed the diagnosis
of cystinosis. She died at the age of 7 years after receiving renal
dialysis for 3 months. The family had a history of one sibling
death at the age of 1 year and 7 months with similar symp-
toms. Samples from the brother and parents were available
for testing.
The proband from family 3 was born to second-cousins
parents and was a result of normal vaginal delivery with a
birth weight of 2 kg. During the neonatal period, the mother
observed the proband having an attack of febrile illness and
drink excessive milk. The child’s illness was associated with
constipation and with failure to gain weight. At the age of
6 months, she was admitted to the hospital to be investigated
for failure to thrive and was found to have rickets, hypophos-
phataemia, hypokalaemia, metabolic acidosis and glucosuria,
suggesting Fanconi syndrome. Then, a slit lamp examination
showed negative result for corneal cystine crystals. At the
age of 3 years, the slit lamp examination was repeated and
conﬁrmed the presence of cystine crystals, and the diagnosis
of cystinosis was made. Cysteamine treatment was refused
by the patients’ parents, and by the age of 3 years and
8 months, the patient began to show symptoms of renal fail-
ure. Samples from the brother and parents were available for
testing.
In family 4, the proband was admitted to the hospital at the
age of 6 months with failure to gain weight, polyuria and poly-
dipsia. The parents were second-cousins with a positive family
history of cystinosis. Physical examination revealed that the
baby was in the 5th percentile for both height and weight. Lab
tests showed evidence of hypokalaemia, hypophosphataemia,
metabolic acidosis, glucosuria and proteinuria, along with
radiological changes of rickets. The ophthalmological
exam was normal at 6 months of age. The leucocyte cystine
level was 2.0 nmol half-cystine/mg of protein at the age
of 1 year and 7 months with typical corneal crystals. Oral
cysteamine therapy was initiated shortly thereafter, and
patient died at the age of 10 years as a result of end-stage
renal failure.
In family 5, the proband was an 11-month-old male
infant that was born to ﬁrst-cousins of Sudanese nationality.
There was a positive family history with unexplained deaths
of 3 siblings during infancy. The proband started at the
age of 4 months to have recurrent episodes of vomiting
and diarrhoea, requiring admission to the hospital on sev-
eral occasions. Upon X-ray, he was found to have widened
wrists, suggesting active rickets. Investigations showed per-
sistent hypokalaemia, hypophosphataemia with acidosis and
a normal anion gap. Urine testing for amino acids showed
generalised aminoaciduria. Based on these ﬁndings, he
was diagnosed with Fanconi syndrome and was started on
appropriate supplements. An ophthalmological evaluation
conﬁrmed the presence of crystals in the cornea suggestive
of cystinosis. Samples from the parents were available for
testing.
In family 6, the parents who were second-cousins
sought genetic counselling because three of their children’s
were died of cystinosis before this study started. The children’s
died at age of 2 months (son), 3 years (daughter) and 2 years
(second daughter). Thus, DNA samples were unavailable from
the children’s. The clinical record for the second daughter
was available at the Paediatric department of King Hussein
Medical Centre in Amman. She was admitted to hospital at
age of 1 year and 6 months with clinical signs resembling Fan-
coni syndrome. At age of admission a slit lamp examination
showed negative result for corneal cystine crystals but her
X-ray showed radiological changes of rickets. Despite the
patient was on regular electrolyte replacement and cys-
teamine treatments, here kidney function deteriorated and
died at the age of 2 years.
Mutation  analysis
The genomic DNA from patients and their available family
members was extracted from whole blood using the Wizard
Genomic DNA Puriﬁcation Kit (Promega, Madison, WI,  USA).
The polymerase chain reaction was performed in an iCy-
cler Thermal Cycler (Bio-Rad, Hercules, CA, USA). The
57-kb deletion was evaluated using a previously described
method.13 Brieﬂy, two independent multiplex PCR reactions
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Fig. 1 – (A) DNA sequence chromatograms for heterozygous
genotype (mother, family 3) of the c.829dupA mutation in
exon 10 of the CTNS gene. (B) DNA sequence
chromatograms for heterozygous genotype (mother, family
1) of the c.890G>A mutation in exon 11 of the CTNS gene.
The arrows indicate the locations of the mutations.
were performed: the ﬁrst multiplex PCR reaction including
the primer pairs LDM1 and D17S829 and another reac-
tion including the LDM2 and exon 4 primer pairs. The
upstream and downstream PCR primers and reaction condi-
tions to amplify CTNS exons 3-12 and the ﬂanking intronic
sequences were essentially as described by Town et al.3 The
promoter primers were designed using the Primer3 algo-
rithm (http://frodo.wi.mit.edu/primer3) according to GenBank
accession number NM 001128425.1 and had the following
sequences: forward, [5′-TGCCAATCTTTCAGCCACAC-3′] and
reverse, [5′-TCTTAGACGGACAGAGCGC-3′]. All of the PCR
products were subjected to bi-directional sequencing using
the Big-Dye Terminator v3.1 Cycle Sequencing Kit from
Applied Biosystems before being applied to an ABI PRISM
310 Genetic Analyser (Applied Biosystems, Foster City, CA,
USA). The sequence data were compared to the normal
CTNS gene sequence (GenBank accession number for the
c-DNA: NM 004937.2; GenBank accession number for genomic:
NG 012489.1) using the ChromasPro 1.34 (Technelysium Pty
Ltd, Australia) software package. Sequence nomenclatures
for the coding and noncoding variants are described in
accordance with the Human Genome Variation Society
Nomenclature standards. The promoter variants are described
in this study by considering the transcription site to be the +1
nucleotide.27
Results
Five different Jordanian families with nephropathic cysti-
nosis from different geographical locations in Jordan and one
Table 1 – Mutations in the CTNS gene characterised in
Jordanian families.
Subject Symptomatology c.829dupA c.890G>A
Family 1
Proband Yes WT/WTa A/A
Father No WT/WT G/A
Mother No WT/WT G/A
Sister No WT/WT G/A
Grandmother No WT/WT G/G
Family 2
Proband Yes WT/829dupA G/A
Father No WT/829dupA G/G
Mother No WT/WT G/A
Brother No WT/WT G/G
Family 3
Proband Yes 829dupA/
829dupA
G/G
Father No WT/829dupA G/G
Mother No WT/829dupA G/G
Brother No WT/829dupA G/G
Family 4
Proband Yes WT/829dupA G/G
Family 5
Proband Yes WT/WT A/A
Father No WT/WT G/A
Mother No WT/WT G/A
Family 6
Father No WT/829dupA G/G
Mother No WT/829dupA G/G
a WT, wild type.
family from Sudan (Family 5) were investigated in this study
for the CTNS mutation. Consanguinity was reported for all
six of the families. All of the probands initially presented
with Fanconi syndrome and rickets. Cystinosis was suggested
by the presence of crystals in the cornea upon ophthalmo-
logical evaluation by age 2 years in most of the probands.
The 57-kb deletion was not found in all of the families and
that was evidenced by the presence of the 250-bp PCR pro-
duct using the LDM2/exon 4 primers and the 266-bp PCR
product by using the LDM1/D17S829 primers (data not shown).
Ampliﬁcation of the coding exons (3–12) for the CTNS gene
followed by bi-directional DNA sequencing identiﬁed three
polymorphisms, −294C>T, −180T>C and −118C>T in the CTNS
promoter region, one silent (c.504G>A; p.Thr168Thr), one mis-
sense (c.779C>T; p.Thr26Ile) variants and two CTNS mutations:
c.829dupA (Fig. 1A) and c.890G>A (Fig. 1B). The proband of
family 2 in this study was compound heterozygous for both
mutations, where c.829dupA was transmitted from the father
and c.890G>A was contributed by the mother (Table 1). Both of
the parents in family 6 were carriers of the c.829dupA muta-
tion, and their affected children who were not available for
testing were presumably homozygous for the same mutation.
Both of the probands of Jordanian family 1 and Sudanese
family 5 were homozygous for the c.890G>A mutation (Table 1).
The C allele encoding Thr amino acid of the c.779C>T
variant was in cis with the mutant alleles for both c.829dupA
and c.890G>A mutations in the Jordanian families, whereas in
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the Sudanese proband, the T allele coding for Ile amino acid
was in cis with mutant A allele for the c.890G>A mutation.
Discussion
This is the ﬁrst molecular study on Jordanian patients with
cystinosis infantile nephropathic cystinosis. The 57-kb dele-
tion was not found in any of the Jordanian probands using two
different multiplex polymerase chain reactions. Our results
agree with previous regional studies in which the 57-kb dele-
tion was not found in Saudis, Egyptians, Emiratis, Turkish
or Iranians.4,7–10 The 57-kb deletion was previously found in
homozygous genotypes in 48 of 108 (44%) patients of European
descendant living in America, and this deletion also accounts
for 34% and 65% of the CTNS mutant alleles in patients of
Spanish and German origin.18,22,29
In this study, we  identiﬁed two frameshift mutations in
the CTNS gene in ﬁve Jordanian families and one family
from Sudan with a history of nephropathic cystinosis. The
c.829dupA (p.Thr277Asnfs*19) mutation, which is located in
exon 10, resulting in an amino acid substitution for residues
277–294 with the exception of the Phe residue at position
282 and a premature stop codon at residue 295 (Glu295X).
The c.829dupA mutation was described in a compound het-
erozygous genotype with the 57-kb deletion in Belgium and
was recently found in a homozygous genotype in three
probands and one sibling from Egypt.7,30 The second muta-
tion, c.890G>A mutation, which is located in exon 11, converts
the Trp 297 TGG codon into a TAG stop codon (p.Trp297X).
The c.890G>A was originally described in a heterozygous
genotype in a male from South Italy with ﬁrst-cousin par-
ents; as well as for the c.779C>T variant that was found
in 5 Italian patients.15 Both of the mutations in this study
were found in the proband of family 2 as a compound het-
erozygous genotype that was not previously described. The
ﬁnding of the compound heterozygous genotype is not usually
expected in a consanguineous family. However, several exam-
ples have been reported in which two different mutations
create compound heterozygotes in consanguineous families
in Mediterranean populations. For example, Lebanese patients
from an extended consanguineous family with Bardet-Biedl
syndrome were found to be heterozygous for two mis-
sense mutations, p.Ser311Ala and p.Val11Gly, in the BBS10
gene.31 Similarly, in an inbred pedigree in an Israeli Arab
family with congenital nephrotic syndrome, two patients car-
ried both p.Gln380X and p.Cys721fs mutations in the NPHS1
gene as a compound heterozygous genotype.32 The case we
report is less extreme in the sense that both mutations
(p.Thr277Asnfs*19 and p.Glu295X) are seen in homozygous
(four Jordanian families) and in heterozygous (one Jorda-
nian family) living in different and distant locations; but
founder effects likely account for their joint occurrence. This
possibility could be further ascertained by additional geno-
typing and analyses of haplotype status in the probands and
families.
The inheritance of the same c.890A mutant allele in cis
with the C allele of the c.779C>T variant in Jordanian and in
cis with the T allele in Sudanese patients suggests an indepen-
dent origin of the same mutation in the Arabic population. The
association of the c.779C allele with both of the mutant alleles
for c.890A and c.829dupA is an additional DNA marker that
can be used for prenatal molecular diagnostics of cystinosis
in Jordanian families.
Both the c.829dupA in exon 10 and c.890G>A in exon
11 resulted in a truncated cystinosin protein that, if stable,
would lack the 6th and the 7th transmembrane domains and
the ﬁve-amino-acid ‘GYDQL’ lysosomal sorting signal at the
c-terminal tail of the protein. Additionally, the c.829dupA
mutation resulted in eight amino acid substitutions within the
ﬁrst nine amino acids of the third cytoplasmic loop, which is
composed of 19 amino acids (280–298) between the ﬁfth and
sixth potential transmembrane domains.24,25 The deletion of
the ﬁrst nine amino acids of this loop (amino acids 280–288)
coupled with the deletion of the deﬁned carboxyl ‘GYDQL’
motif resulted in the complete relocalisation of cystinosin-
GFP to the plasma membrane without a signal remaining
in the lysosomes.24,25 Therefore, both of the mutations that
were identiﬁed in this study potentially resulted in the partial
redirection of cystinosin to the plasma membrane, and the
c.829dupA mutation may also result in the complete relocali-
sation of cystinosin to the plasma membrane.
The proband of family 4 who was heterozygous for the
c.829dupA mutation inherited haplotype −294T/T, −180C/C
and −118T/T for the three polymorphisms in the CTNS pro-
moter region spanning −85 to −406 nucleotides relative to
the CTNS +1 transcription site. The C-to-T substitution is
294 bp upstream of the transcription site of the CTNS gene,
which is part of the Sp1 consensus binding (−299 to -293)
sequence in the CTNS promoter.24 An in vitro study using
a luciferase vector reporter gene construct harbouring the
−294T allele that was transfected transiently in human kid-
ney tubular cells (HK2) showed a 30% reduction in luciferase
transcriptional activity compared to −294C construct.28
Similarly, a functional study showed an 81% reduction in CAT
reporter gene constructs harbouring the −295C mutant allele
of the CTNS promoter.24 However, four patients carrying the
−295G>C mutation were also carrying two allelic mutations
in the coding region for the CTNS gene, which may contradict
a role of promoter mutation in the disease.15 In proband 4,
the second mutated allele may be within the CTNS intronic
regions, which were not sequenced in this study, and this
mutation may affect the splicing processes.16
There is evidence for the allelic heterogeneity of nephritic
cystinosis disease in Arabic patients, as twenty-three known
and new mutations in the CTNS mutation have been
characterised in Arabic individuals thus far.4–8 These muta-
tions spread across the CTNS gene, mainly in the coding exon
number 3 and exons 6–12, and include several types, includ-
ing missense, nonsense, frameshift and splicing mutations.
Twelve of the 23 mutations were novel.4–8 Four muta-
tions, including the two mutations that were described in
this study (Thr277Asnfs*19 and p. Trp297), i.e., p. G308R
and p.G339R, were characterised in more  than one Arabic
nationality and have also been characterised in other parts
of the world.4,7,9,15,18,29,30
However, the c.681G>A; p.E227E mutation that substituted
for the last base of exon 9 of the CTNS gene and created a new
cryptic donor site was previously found exclusively in several
patients from Middle Eastern countries but not in Jordan.4,7,9,10
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Despite the notable prevalence of the c.681A mutant allele
in homozygous and heterozygous genotypes in cystinosis
patients in the Middle East, further haplotype analysis for
chromosome 17 is required to determine whether this is a
founder mutation in the region. The geographical distribution
of the c.681G>A allele in several Middle Eastern populations
was analysed by Soliman et al., who proposed that the origin
of this mutation is in Eastern Iran.7 Similarly, putative founder
mutations, such as c.753G>A and c.898-900 24del27, have been
characterised in French Canada and in the western province
of Brittany, France, respectively.33,34
In summary, we  have identiﬁed two loss-of-function muta-
tions in the CTNS gene in several Jordanian families and
one family from Sudan. These two mutations extend the
regional mutation database for the orphan disease cystinosis.
Both of the mutations were originally described in heterozy-
gous genotypes in European patients and have been found in
Egyptians, Jordanians and Sudanese individuals. These results
will facilitate the molecular genetic diagnosis of cystinosis in
Jordan.
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